Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
{{output}}
Background: A comprehensive quantitative analysis was conducted to examine patient preferences for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment attributes. ... ...
